Business Wire

ESI

18.9.2023 08:01:26 CEST | Business Wire | Press release

Share
International Equal Pay Day: ESI Group Fosters Gender Equity at Work and Globally Raises Salaries for Women Returning From Maternity Leave

Regulatory News:

ESI Group (Paris:ESI), the world-renowned simulation and virtual prototyping software provider for industry, is actively working to ensure gender equality in the workplace and is implementing actions aimed at eliminating pay gap discrimination.

September 18th commemorates International Equal Pay Day, an occasion dedicated to raising awareness about unequal pay and advocating for the closure of the gender pay gap. Over the past two decades, the pay gap has been shrinking, albeit slowly. In 2022, it was March 15th. Back in 2005, Equal Pay Day was April 19th. This year, Equal Pay Day for all women was Tuesday, March 14th, 2023 whereas Moms’ Equal Pay Day occurred on August 15th. Acknowledging this disparity, the Group has taken proactive steps by extending the French best practice consisting of increasing the salaries of women returning from maternity leave to the 17 other countries where the Group operates: all women returning from maternity leave were guaranteed a salary increase, at a minimum, in line with their respective country's budget. This year, the 7 employees who came back from maternity leave benefited from this.

Furthermore, in line with ESI commitments to the United Nations Women's Empowerment Principles (WEP), the Group monitored and maintained close vigilance over the percentage of employees receiving salary increases by gender, as well as the average percentage increase by gender. ESI Group maintains its steadfast gender-neutral compensation policy, using objective market data tailored to employee positions and organizational levels, irrespective of gender. It actively promotes gender equality and proactively recommends salary increases to campaign-involved managers, with a strong focus on fine-tuning gender equity in the salary review process this year.

Introduced in May 2022, the Women@ESI network, a dedicated initiative aimed at fostering internal collaboration among employees and establishing an open communication platform for exchanging ideas that enhance the representation and empowerment of women, continues to evolve. Moreover, the Group has been recognized for its initiatives to promote gender equity in the workplace, among numerous other CSR initiatives. ESI Group was awarded a Silver Grade from the Ethifinance ESG rating on the 28th of July 2023 (formerly Gaia index), also contributing to the UN 5th Sustainable Development Goals (SDG) "Gender Equality".

Yannick Charron, Senior Vice President of Human Resources at ESI Group declares: “At the start of the year, ESI Group made a resolute commitment to propel gender equality in the workplace, marketplace, and our community by formally endorsing the United Nations Women's Empowerment Principles (WEP). Our steadfast dedication remains persistent as we actively cultivate an environment free from discrimination. This remains a paramount goal for our organization, and we continuously refine our efforts to ensure gender equality at work and to make ESI Group an exemplary workplace for all.”

About ESI Group

Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high-stakes concerns -environmental impact, safety & comfort for consumers and workers, and adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, and heavy industry, ESI is present in more than 18 countries, employs 1000 people around the world, and reported 2022 sales of €130 million. ESI is headquartered in France and is listed in compartment B of Euronext Paris.

For further information, go to www.esi-group.com.

https://www.esi-group.com/company/who-we-are

Follow ESI LinkedIn | Facebook | Twitter | YouTube

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230917848256/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye